FDA approves Infilbray (venglustat) for neurological symptoms of Type 3 Gaucher disease
The agency cleared the oral drug on November 18, 2026, as the first treatment for GD3's brain and nervous system symptoms in patients weighing at least 15 kg.
The FDA announced on November 18, 2026 that it had approved Infilbray (venglustat) tablets as the first treatment for the neurological symptoms of Type 3 Gaucher disease in adults and pediatric patients weighing at least 15 kg, approximately 33 pounds.1
Type 3 Gaucher disease, or GD3, is a rare inherited disorder. According to the FDA, it is a condition in which the body cannot properly break down fatty substances called glucosphingolipids due to a deficient or malfunctioning enzyme.1 Unlike type 1 Gaucher disease, GD3 also affects the brain and nervous system, causing difficulties with balance, coordination, speech, memory, and thinking, with symptoms that can worsen progressively.1
The drug's mechanism differs from existing enzyme therapies in that Infilbray works as a glucosylceramide synthase inhibitor, reducing the buildup of harmful substances throughout the body and within the brain.1 It crosses the blood-brain barrier to reduce accumulation of harmful substances in the body and brain.1
Approval rested on a randomized, double-blind, multicenter study of 43 patients aged 12 years and older with GD3 who had previously been treated with enzyme replacement therapy and had achieved systemic disease stabilization, with participants receiving either oral Infilbray or intravenous enzyme replacement therapy every two weeks for 52 weeks.1 Effectiveness was measured using two assessments covering neurological symptoms including ataxia and cognitive function, and at Week 52 patients on Infilbray showed improvement on a combined measure compared to those on enzyme replacement therapy for non-neurologic manifestations.1
On safety, the FDA said the most frequently reported side effects include gastrointestinal symptoms and adverse effects on mood, with serious psychiatric risks including suicidal ideation and behavior also reported.1 Animal studies identified potential clouding of vision in younger patients and adverse effects on fetal development during pregnancy.1
Infilbray was granted Orphan Drug designation and Priority Review, and the approval was granted to Genzyme Corporation, a Sanofi Company.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.